1.

Systems evaluating therapeutic effects of sorafenib for HCCs according to the WHO, RECIST, EASL, mRECIST, Choi and RECICL criteria

Response category	WHO Criteria	RECIST 1.0 and 1.1	EASL criteria	mRECIST	Choi criteria	RECICL criteria
HCC, hepatocellular carcinoma; WHO, World Health Organization; RECIST, Response Evaluation Criteria in Solid Tumors; EASL, European Association for Study of the Liver; mRECIST, modified RECIST; RECICL, Response Evaluation Criteria in Cancer of the Liver; TE4, 100% tumor necrosis or size reduction; TE3, 50%–100% tumor necrosis or size reduction; TE2, neither TE3 nor TE1; TE1, ≥50% increase in tumor size.
Complete response (CR)	Disappearance of all lesions	Disappearance of all lesions. RECIST 1.1 added: pathologic lymph node reduction	Disappearance of enhancing area inside treated location	Disappearance of intratumoral enhancing area	Disappearance of all lesions	TE4 in both target and non-target lesions. No new lesions
Partial response (PR)	≥50% decrease in sum of cross-product of target lesions	≥30% decrease in sum of diameters of target lesions	≥50% decrease in sum of enhancing area	≥30% decrease in sum of diameters of enhancing area	≥10% decrease in sum of diameters or ≥15% decrease in tumor density. No obvious progression of nonmeasurable disease	TE4 in target lesions and TE3 or TE2 in non-targets lesions with no new lesions. Or TE3 in target lesions and non-TE1 in non-target lesions with no new lesions
Stable disease (SD)	Neither PR nor PD	Neither PR nor PD	Neither PR nor PD	Neither PR nor PD	Neither PR nor PD. No symptomatic deterioration attributed to tumor progression	TE2 in target lesions and non-TE1 in non-target lesions with no new lesions
Progressive disease (PD)	≥25% increase in the cross-product of target lesions or appearance of new lesions	≥20% increase in sum of diameters. RECIST 1.1 added: must have at least 5 mm absolute increase in sum	≥25% increase in sum of enhancing area or appearance of new lesions	≥20% increase in sum of diameters of enhancing area	≥10% increase in tumor size and does not meet criteria of PR by tumor density. New lesions. New intratumoral nodules or increase in the size of the existing intratumoral nodules	TE1 in target or non-target lesions or presence of new lesions